Shandong Pharmaceutical Glass Co., Ltd

Total Valuation

Shandong Pharmaceutical Glass Co., Ltd carries a market capitalization of 12.40B, placing it among publicly traded companies globally. Its enterprise value stands at 9.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Shandong Pharmaceutical Glass Co., Ltd currently has 663.61M shares outstanding.

Valuation Ratios

Shandong Pharmaceutical Glass Co., Ltd trades at a trailing price-to-earnings ratio of 25.05. The price-to-sales ratio is 2.75, and the price-to-book ratio stands at 2.51.

Enterprise Valuation

On an enterprise value basis, Shandong Pharmaceutical Glass Co., Ltd trades at an EV/EBITDA multiple of 13.29 and an EV/FCF ratio of 52.75. The EV/Sales ratio of 2.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.29 provides insight into valuation relative to core operating earnings.

Financial Position

Shandong Pharmaceutical Glass Co., Ltd maintains a current ratio of 3.79, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.51, indicating moderate leverage, while an interest coverage ratio of 605.24 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Shandong Pharmaceutical Glass Co., Ltd posts a return on equity of 10.11 and a return on invested capital of 7.26.

Taxes

Over the trailing twelve months, Shandong Pharmaceutical Glass Co., Ltd has paid 100.41M in income taxes, reflecting an effective tax rate of 16.84.

Stock Price Statistics

Shandong Pharmaceutical Glass Co., Ltd's stock has declined approximately -14.92945% over the past 52 weeks. The 50-day moving average sits at 18.56, while the 200-day moving average is 19.82.

Income Statement

Over the trailing twelve months, Shandong Pharmaceutical Glass Co., Ltd generated 4.52B in revenue and converted that into 495.89M in net income, yielding earnings per share of 0.74. EBITDA reached 731.29M, while operating income came in at 731.29M.

Balance Sheet

Shandong Pharmaceutical Glass Co., Ltd holds 2.74B in cash and equivalents against 42.38M in total debt, resulting in a net debt position of -2.54B. Total book value stands at 4.95B, with working capital of 4.49B providing operational flexibility.

Cash Flow

After subtracting -183.30M in capital expenditures, free cash flow totaled -183.30M - equivalent to -0.27 per share.

Margins

Shandong Pharmaceutical Glass Co., Ltd operates with a gross margin of 33.44, reflecting its pricing power and cost economics. The operating margin of 16.17 and net profit margin of 10.97 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Shandong Pharmaceutical Glass Co., Ltd's most recent stock split took place on June 20, 2019 with a 5:7 split ratio.

Scores

Shandong Pharmaceutical Glass Co., Ltd posts an Altman Z-Score of 6.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.